Biotech · South San Francisco, CA · Founded 2023 · Privately Held (backing)
Developer of life-changing medicines designed through the transformative power of artificial intelligence. Xaira Therapeutics is based in South San Francisco, CA and was founded in 2023. It was valued at $3.5 billion at its early-stage round in Aug 2025, the last priced event on record. It has raised $1.3 billion across 1 recorded round; the latest was a $1 billion Series A in Apr 2024.
PMV mark · valuation
$3.5B
Oct 2026
Priced at
its early-stage round
Aug 2025
Total raised
$1.3B
Last round
Series A
Apr 2024
No prints on record
No secondary trades in Xaira Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Xaira Therapeutics with a free account
·The complete investor list: 20 names
·Watch Xaira Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Xaira Therapeutics stock.
